NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) -

- Norgine to receive a significant upfront payment and undisclosed
sums in sales milestones along with double-digit percentage
royalties
- Norgine retains full commercial rights to PLENVU® in all unlicensed
countries

NORGINE B.V. (Norgine), a leading European specialist
pharmaceutical company and KOREA PHARMA CO., LTD. (Korea Pharma), a
premier pharmaceutical manufacturer in Korea, today announced an
exclusive licence and distribution agreement in the Republic of Korea
by which Korea Pharma will commercialise Norgine's product PLENVU®.

(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

(Photo:
https://mma.prnewswire.com/media/802064/NORGINE_KOREA_PHARMA.jpg )

PLENVU® is a lower-volume (1L) polyethylene glycol (PEG) based
bowel preparation for colonoscopy in adults. It is the first
lower-volume bowel preparation to show superior segmental cleansing
of the colon vs. standard of care.[1]

Jae-Don Park, CEO and Chairman of Korea Pharma said, "Building on
our strong presence and knowledge in the South Korea market, we look
forward to making PLENVU® available to healthcare professionals to
help them to improve colonoscopy outcomes as well as patient
experience and adherence to bowel cleansing instructions."

"We are excited about our collaboration with Korea Pharma, a
trusted player," said Peter Stein, Chairman and Chief Executive
Officer of Norgine. "South Korea is an important market and this
partnership reflects the breadth and scope of Norgine's capabilities
to build a strong network and reach out to more patients worldwide."

PLENVU® is currently available in mainland Europe (except France
and Sweden) and Australia via Norgine and in the USA via its partner
Salix Pharmaceuticals.[2] For further information on PLENVU®in the EU
visit http://www.expertiseincolonoscopy.com/plenvu

http://www.norgine.com

Follow us @norgine

Notes to Editors:

About PLENVU®

PLENVU®, Powder for Oral Solution (PEG 3350, Sodium Ascorbate,
Sodium Sulfate, Ascorbic Acid, Sodium Chloride, and Potassium
Chloride), is indicated in adults for bowel cleansing prior to any
procedure requiring a clean bowel.

About Colorectal Cancer and colonoscopy

Colorectal cancer is the second most common cause of
cancer-related mortality world-wide.[3] Colorectal cancer is largely
preventable, with early detection being associated with a 90% cure
rate.[4] Colonoscopy is an effective method for colorectal cancer
screening and has been shown to reduce both the incidence and
mortality of colorectal cancer when applied in the general
population. Inadequate pre-colonoscopy bowel cleansing reduces the
diagnostic accuracy of colonoscopy, particularly for the detection of
smaller lesions and sessile (slightly flattened) polyps. This may
result in repeated procedures, thereby potentially increasing patient
burden, resource requirement and costs and can possibly delay the
initiation of treatment.[5],[6],[7]

About Norgine

Norgine is a leading European specialist pharmaceutical company
with a direct commercial presence in all major European markets.
Norgine specialises in gastroenterology, hepatology, cancer and
supportive care. In 2017, Norgine's total net product sales were EUR
345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial,
development and manufacturing operations and manages all aspects of
product development, production, marketing, sale and supply.

In 2012, Norgine established a complementary business, Norgine
Ventures, supporting innovative healthcare companies through the
provision of debt-like financing in Europe and the US. For more
information, please visit http://www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of
companies.

About Korea Pharma

Since it was established in 1974, Korea Pharma has established a
high-tech current good manufacturing practice (cGMP) facility for
world-class GMP. Korea Pharma specialises in gastroenterology
(including bowel preparation), antibiotics and diseases of the
central nervous system (CNS). With this agreement signed today with
Norgine, Korea Pharma has the opportunity to make a quantum leap in
gastroenterology. Korea Pharma entered into a technology agreement
for the treatment of dementia with Kyungsang national university in
2014.

References

1. Repici A., Amlani B., Uebel P., Schreiber S. Superior high-quality
colon cleansing with 1L NER1006 versus sodium picosulfate +
magnesium citrate, 2L polyethylene glycol + ascorbate, or oral
sulfate solution: Post hoc pooled analysis of three randomised
phase 3 clinical trials. #P0159. Monday 22 October. 12:30 - 13:30
CET. UEGW 2018
2. In Austria, Spain and the Netherlands it is known as PLEINVUE®
rather than PLENVU®
3. World Health Organisation.
https://www.who.int/news-room/fact-sheets/detail/cancer Last
accessed December 2018
4. American Cancer Society. https://www.cancer.org/cancer/colon-rect
al-cancer/detection-diagnosis-staging/detection.html Last accessed
December 2018
5. Bechtold ML, Mir F, Puli SR et al. Optimizing bowel preparation
for colonoscopy: a guide to enhance quality of visualization. Ann
Gastroenterol 2016; 29: 137 - 146
6. Brenner H, Stock C, Hoffmeister M. Effect of screening
sigmoidoscopy and screening colonoscopy on colorectal cancer
incidence and mortality: systematic review and meta-analysis of
randomised controlled trials and observational studies. BMJ 2014;
348: g2467
7. Baxter NN, Warren JL, Barrett MJ et al. Association between
colonoscopy and colorectal cancer mortality in a US cohort
according to site of cancer and colonoscopist specialty. J Clin
Oncol 2012; 30: 2664 - 2669

ots Originaltext: NORGINE B.V. and KOREA PHARMA CO., LTD.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Eleni Fistikaki +44 (0)1895-826227 or +44 (0)7825-389477
Clara Bentham +44 (0)1895-826654 or +44 (0)7734-367883
contact@norgine.com
Media Contacts for Korea Pharma: Youngchan Choi +82-2-2162-8418
youngchan.choi@koreapharma.co.kr

Original-Content von: NORGINE B.V. and KOREA PHARMA CO., LTD., übermittelt durch news aktuell